Clostridium difficile (C. difficile) is a significant cause of infectious disease deaths in the United States, constituting a serious public health burden. According to the Centers for Disease Control and Prevention, nearly 250,000 people become infected with C. difficile during hospital stays each year, surpassing the number of methicillin-resistant Staphylococcus aureus infections.
Upon successful completion of this activity, participants should be better able to:
- Apply current evidence-based guidelines for the overall management of C. difficile infection.
- Incorporate treatment strategies that may reduce C. difficile infection recurrence, as well as antibiotic resistance.
Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV. Upon successful completion of these activities, participants should be better able to:
- Apply updated evidence-based guidelines and recommendations when selecting initial treatment for patients with human immunodeficiency virus (HIV)
- Select and optimize HIV treatment regimens based on clinical safety and efficacy, propensity for resistance, and patient characteristics.
- Consider patient preferences when selecting HIV treatment regimens to increase adherence and compliance to therapy.
- Implement effective switching strategies, as necessary, in patients who are virologically suppressed, have become virologically resistant to therapy, or who have become nonadherent.